

7/14/06

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: July 14, 2006

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	Unassigned
Filing Date	1/14/2005
First Named Inventor	Hiromitsu FUSE
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	023312-0127

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/L.W./	A1	6,555,371	B1	SAITO, Masaki	04/29/2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/L.W./	A2	JP	2000-333682	A	Seikagaku Kogyo Co. Ltd.	12/05/2000		A
	A3	JP	11-18778	A	Seikagaku Kogyo Co. Ltd.	01/26/1999		A
	A4	WO	03/078624	A1	Takeda Chemical Ind. Ltd.	09/25/2003		A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/L.W./	A5	BOBRYSHVET et al., "Phenotype determination of anti-GM3 positive cells in atherosclerosis lesions of the human aorta, Hypothetical role of ganglioside GM3 in foam cell formation," Biochimica et Biophysica Acta, 2001, vol. 1535, pp. 87-99.	
	A6	FUKUMOTO et al., "Expression Cloning of Mouse cDNA of CMP-NeuAc:Lactosylceramide α2,3-Sialyltransferase, an Enzyme That Initiates the Synthesis of Gangliosides," J. Biol. Chem., April 2, 1999, vol. 274, no. 14, pp. 9271-9276.	
	A7	HARA et al., "Characterization and Changes of Glycosphingolipids in the Aorta of the Watanabe Hereditary Hyperlipidemic Rabbit," J. Biochem., 1991, vol. 109, pp. 904-908.	
	A8	MELKERSON-WATSON et al., "Purification to Apparent Homogeneity by Immunoaffinity Chromatography and Partial Characterization of the GM3 Ganglioside-forming Enzyme, CMP-Sialic Acid:Lactosylceramide α2,3-Sialyltransferase (SAT-1), from Rat Liver Golgi," J. Biol. Chem., March 5, 1991, vol. 266, no. 7, pp. 4448-4457.	
	A9	PROKAZOVA et al., "Ganglioside GM3 stimulates the uptake and processing of low density lipoproteins by macrophages," Biochemical and Biophysical Research Communications, May 31, 1991, vol. 177, no. 1, pp. 582-587.	
	A10	USUKI et al., "Toward the Understanding of Glycopilid GM3 Functions - Application of Metabolic Inhibitors," Nippon Yuka Gakkaishi, 1997, vol. 46, no. 10, pp. 1075-1086 (with English abstract).	

Examiner
Signature

/Louis Wollenberger/

Date
Considered

06/16/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1650547.1